Jiangsu Nhwa Pharmaceutical Company Limited operates within the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Jiangsu Nhwa Pharmaceutical Company Limited with three other
companies in this sector in China:
Kingworld Medicines Group Limited
sales of 1.05 billion Chinese Renmimbi [US$155.69 million]
of which 90%
was Distribution sales of pharmaceutical and),
Zhejiang Zhenyuan Co., Ltd.
(2.44 billion Chinese Renmimbi [US$360.54 million]
of which 84%
was Medicine Wholesales), and
China Pioneer Pharma Holdings Ltd
(1.79 billion Chinese Renmimbi [US$264.57 million]
of which 57%
was Products sold via the provision of co-pr).
During the year ended December of 2016, sales at
Jiangsu Nhwa Pharmaceutical Company Limited were 3.02 billion Chinese Renmimbi (US$445.89 million).
increase of 9.1%
versus 2015, when the company's sales were 2.77 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Jiangsu Nhwa Pharmaceutical Company Limited
(and since 2011, sales have increased a total of 90%).
Sales of Medical Industrial Manufacturing saw an increase
15.7% in 2016, from
1.42 billion Chinese Renmimbi to 1.65 billion Chinese Renmimbi.
Not all segments of Jiangsu Nhwa Pharmaceutical Company Limited experienced an increase in sales in 2016:
sales of Other Operation fell 97.4% to 1.00 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).